Acute promyelocytic leukemia (APL) is distinguished from other acute myeloid leukemias (AMLs) by cytogenetic, clinical, as well as biological characteristics. The hallmark of APL is the t(15;17), which leads to the expression of the PML/RARa fusion protein. PML/RARa is the central leukemia-inducing lesion in APL and is directly targeted by all trans retinoic acid (t-RA) as well as by arsenic, both compounds able to induce complete remissions. This review focuses on potential stem cell involvement in APL outlining the knowledge about the APL-initiating stem cell and the influence of PML/RARa on the biology of the hematopoietic stem cell. Moreover, the importance of the blockage of t-RA signaling by the PML/RARa for the pathogenesis of APL is discussed, taking the relevance of the t-RA signaling pathway for the global hematopoiesis into account.
Introduction
Acute myeloid leukemias (AMLs) are characterized by an accumulation of abnormal hematopoietic progenitors in the bone marrow and in the peripheral blood exhibiting the morphology of a certain stage of myeloid differentiation, which defines the respective subtype according to the FrenchAmerican-British (FAB) classification of AML.
1 Acute promyelocytic leukemia (APL) is thus classified as FAB M3. 1 The AML phenotype seems to be maintained by an increased proliferation of these blast cells, which is considered to result from the combination of two components: (i) the block of differentiation hindering progenitors to reach the postproliferative stage and to undergo programmed cell death subsequently and (ii) an increased capacity for self-renewal of the leukemic progenitors. The cytogenetic hallmark of APL is the t(15;17) translocation. In rare cases alternative translocations are found, such as t(11;17)(q23;21), t(5;17), or other sporadic translocations that constantly involve the RARa locus on chromosome 17 (for an extensive review, see Melenick and Licht 2 ). Clinically, APL is distinguished from other AML subtypes by (i) life-threatening bleeding disorders; 3 (ii) achievement of complete remissions (CRs) in about 90% of APL patients upon treatment with all trans retinoic acid (t-RA); 4 and (iii) induction of CRs in 75-90% of APL patients upon exposure to low-dose arsenic trioxide. 5 In contrast to other AML subtypes, the APL blasts are biologically characterized by (i) their responsiveness to the differentiation-inducing activity of t-RA in vitro, which proves that t-RA induces CRs in the patients by the induction of terminal differentiation of the blasts 6 and (ii) their response to the dual activity of trivalent arsenic, which induces a high rate of apoptosis as well as a considerable rate of differentiation in APLderived cells. 7 APL represents a paradigm of AML, since APL served as a model enabling researchers to first prove (a) the functional relevance of the differentiation block in the induction of a malignant leukemic phenotype; (b) the feasibility to treat malignancies by the induction of differentiation; 8, 9 (c) the direct relationship between a specific genetic aberration -such as the APL-specific translocation products PML/RARa, PLZF/RARa, as well as NPM/RARa -and the leukemic differentiation block; [10] [11] [12] and (d) the proof of principle for the therapeutic potential of a targeted therapy was also obtained on APL cells, although the exact target -the PML/RARa -of the t-RA therapy was identified later. 13 Of particular interest is the fact that nearly all biological and biochemical features induced by the main translocation product PML/RARa can be reverted by t-RA. 2 Furthermore, the alternative APL-associated translocation products -such as PLZF/RARa or NPM/RARa -introduce additional biological properties, in particular resistance to t-RA and/or to arsenic, strengthening the role of APL as a malignant model disease.
PML/RAR and the t-RA signaling in hematopoiesis APL provided the 'proof of principle' that the induction of terminal differentiation in leukemic blasts re-establishes their potential to undergo apoptosis comparable to normal blood cells. 9 The response to pharmacological doses of t-RA (10 À6 M) is mediated by PML/RARa. The expression of PML-RARa considerably enhances the sensitivity of U937 cells to t-RA-induced differentiation. 10 In HL-60R, which is an HL-60 subclone resistant to t-RA due to the presence of a dominant-negative RARa, 14 the responsiveness to t-RA is restored by the expression of PML/RARa.
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On the other hand, PML/RARa is a repressor of physiological t-RA signaling. Unliganded PML/RARa -comparable to unliganded wild-type RARa -represses t-RA target promoters, but the repression by RARa -as compared to PML/RARa -is releasable by a lower concentration of t-RA, 15, 16 as confirmed by the observation that the histone-deacetylase (HDAC)-recruiting corepressor complex is more strongly bound to PML/RARa than to RARa. [17] [18] [19] Furthermore, unliganded PML/RARa recruits not only HDAC activity but also methylase activity by binding to Dnmt1 as well as to Dnmt3a, which leads to the methylation of t-RA target promoters, such as the RARb2 promoter, in APL blasts as well as in NB4 cells and in U937 cells expressing PML/RARa.
Pathogenetic significance of the PML/RARa-induced block of t-RA signaling
To understand the importance of the blockage of t-RA signaling by PML/RARa for the pathogenesis of APL, one has to consider the role of t-RA signaling in normal hematopoietic progenitors as well as the effect of the interruption of t-RA signaling on global hematopoiesis. The in vitro exposure of normal early hematopoietic stem cells (HSCs) to t-RA not only induces differentiation but mainly selects immature progenitors. 20 Moreover, mice lacking the t-RA-specific receptor RARa do not exhibit an impairment of granulopoiesis or hematopoiesis. 20, 21 Furthermore, vitamin A-deficient mice or mice treated with a t-RA antagonist accumulate more immature granulocytes in the bone marrow. 21 The hypothesis that t-RA may be involved in the hematopoietic differentiation is supported by the demonstration that HL-60 cells undergo granulocytic differentiation upon incubation with pharmacological dosages (10 À6 M) of t-RA. 22 These data suggest that t-RA signaling is dispensable for normal hematopoiesis, and the exact pathogenetic significance of the PML/RAR-induced block of t-RA signaling remains to be resolved.
PML/RARa and the HSC
Assuming that the block of t-RA signaling may be dispensable for the pathogenesis of APL, one has to turn back to the origin of leukemia -the leukemia-initiating cell (LIC) or the leukemic stem cell.
Neoplastic cells and normal stem cells share the capacity of unlimited self-renewal. Leukemias are considered to be malignancies initiated by genetic alterations occurring in HSCs. Following the cell division of a normal hematopoietic cell, the 'daughters' of the 'stem cell' can either be committed to differentiate, to undergo apoptosis, or to remain a stem cell with the potential for self-renewal. These cell fate 'decisions' determine the composition of the cell pool constituting normal hematopoiesis. Hence, it is of fundamental significance for the understanding of the pathogenesis of APL and AML to disclose whether and how PML/RARa influences the biology of the stem cell.
Is PML/RARa already present in the HSC?
First one has to clarify whether PML/RARa is already present in the early stem cell and at which level the APL-associated translocation occurs. The answer to this question would also resolve whether APL is a stem cell disorder or a reacquisition of stem cell characteristics of cells already committed along a specific lineage. 23 Moreover, it would resolve whether the hematological failure in the clinical picture of APL as well as of AML is mainly due to a global differentiation block or to a space-consuming tumor, compressing the normal hematopoiesis. It has to be taken into account that the expression of PML/ RARa is driven by the PML promoter, which is considered to be ubiquitously activated. Thus, one can speculate that PML/RARa is immediately present in the cell in which the t(15;17) occurs. The occurrence of t(15;17) already at the early stem cell levels may influence not only the functionality of myeloid precursors in the bone marrow but also of other cells derived from the early stem cell.
Which is the leukemia-initiating cell in APL?
Most human AML cells have a limited capacity to proliferate, suggesting that the leukemic clone may be maintained by a rare population of stem cells. Little is known about the target cell within the HSC hierarchy susceptible to leukemic transformation, neither are the mechanisms that determine the phenotypic and clinical subtypes of AML defined.
There are two ways to characterize the earliest LIC cell. One is to isolate it from an already established human AML-blast population by determining the SCID leukemia-initiating cell -SL-IC -in NOD-SCID mice. The second way is to introduce serially the genetic alterations considered indispensable for the leukemogenesis in a well-defined stem cell population.
SL-IC derived from AML-M1, -M2, -M4, and -M5 are found in the CD34 þ /CD38À compartment, the same cell type constituting the SCID-repopulating cell in the nonleukemic CD34 þ cell population. 24, 25 Thus it seems that normal primitive cells, rather than committed progenitor cells, are the targets for the leukemic transformation. In vivo, the SL-ICs differentiate into leukemic blasts, indicating that the leukemic clone is organized in a hierarchical order. 24, 25 The frequency of these SL-ICs in the peripheral blood of AML patients is very low, constituting one engraftment unit in 2.5 Â 10 5 cells. There is evidence that these cells are less mature than colony-forming cells. 24 Actually, it is impossible to determine the frequency of SL-ICs in APL, because APL blasts do not engraft in NOD-SCID mice. 25 To the best of our knowledge, there is only one study determining the cell lineage distribution of PML/RARa. PML/ RARa is detected in BFU-e as well as in CFU-GM derived from APL blasts by RT-PCR-based techniques only in two of five APL patients, indicating that PML/RARa is expressed in early progenitor cells in most but not all cases. 26 These data hint at the possibility of PML/RARa expression in all myeloid lineages; nevertheless, further studies are needed to corroborate these findings.
The second way to characterize the earliest LIC cell is to introduce serially the genetic alterations considered indispensable for the leukemogenesis in a well-defined stem cell compartment. In the case of APL, this means to introduce PML/ RARa, RARa/PML plus mutated Flt-3 or c-kit plus bcl-2.
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The currently available PML/RARa transgene models do not allow the identification of the LIC in APL and AML. In fact, most of the already established in vivo models of PML/RARa-positive leukemias are based on PML/RARa-transgenes alone [30] [31] [32] [33] [34] or in combination with mutated Flt3, a molecule also considered to be crucial in the pathogenesis of AML. 35 PML/RARa does not allow the generation of a transgenic mouse if its expression is driven by a promoter of a housekeeping gene such as b-actin. 31, 32 The generation of PML/RARa transgenic mice was only possible by targeting the expression of PML/RARa to promyelocytes employing the human cathepsin G (hCG) promoter. 31, 32 The induction of PML/RARa expression at the promyelocytic stage of differentiation would correspond to a late appearance of the t(15;17) translocation. At the promyelocytic stage of differentiation, the cells should be fully committed to the granulocytic/monocytic differentiation, most likely without an influence on the erythroid and megakaryocytic differentiation pathways. In fact, there are two disease stages: at a preleukemic stage of the disease, thrombopoiesis as well as erythropoiesis were not impaired, indicating no influence on megakaryocytic or erythroid precursors in the presence of alterations of the WBC, as expected by the already fully committed target cell at the onset of transgene expression. The fact that anemia and thrombocytopenia become pronounced in overt leukemia strongly suggests that space consumption by an increasing tumor load is responsible for the suppression of erythropoiesis and thrombopoiesis in these mice.
The expression of PML/RARa under the control of the MRP8 promoter in early myeloid cells not defined exactly most likely does not target the earliest HSCs. 33 The onset of a PML/RARa expression at a later stage of differentiation using the CD11b promoter only impairs differentiation, but cannot induce overt leukemia. 30 APL blasts are only rarely CD11b positive.
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A major contribution to answer the question of the LIC and the effect of PML/RARa on myeloid cells derived from the HSCs could be provided by a transduction/transplantation model of PML/RARa-positive leukemia. Such a transduction/transplantation leukemia model not only allows a more refined characterization of subpopulations of the stem cell compartment but also the establishment in an immunocompetent environment. It has been shown that lineage-depleted (linÀ) murine bone marrow cells retrovirally transduced with PML/RARa and then transplanted into lethally irradiated recipient mice give raise to leukemia. 36 The murine linÀ cell population is a heterogeneous bulk of early hematopoietic progenitors, but it is not known as to which exact grade of commitment to the myeloid lineages these cells already present or acquire during their in vitro manipulations. Employing a more precise characterization of the transduced/transplanted target cells, that is by sorting for c-kit, Sca1 and Thy1.1 low and Flk2 þ /À23 isolating long-term HSCs, this model should render it possible to further define the characteristics of the LIC in PML/RARa-positive leukemia and the role of the global differentiation block for the induction of the AML phenotype. A further problem of this transduction/ transplantation model may be the retrovirus-based transduction, which exclusively targets proliferating cells. To transduce effectively all potential LIC, the system should be shifted to a lentivirus-based transduction model, enabling the researcher to also target nonproliferating cell population. 37 Such an approach would permit one to study the exact contribution of each known genetic alteration to the induction of the leukemic phenotype without the background of chromosomal aberrations acquired during the development of late-onset leukemia in the PML/ RARa-transgenic mice. [38] [39] [40] PML/RARa and the differentiation of HSC Grignani et al 41 showed that PML/RARa enables human CD34 þ /linÀ cells to reach the promyelocytic level of differentiation but not to go further along the erythroid or the thrombocytic lineage, even if cells are cultivated in an adequate cytokine cocktail. These data strongly suggest a global differentiation block, which functions -at least for the erythroid and thrombocytic lineages -already at a very early level, whereas the granulocytic precursors are blocked at a later stage of differentiation: at the promyelocytic level.
PML/RARa as well as other APL-associated translocation products block myeloid differentiation in several cell systems. In fact, PML/RARa is able to block monocytic differentiation induced by a variety of stimuli, such as G/GM-CSF and VitD 3 . 10, 11, 15, 42 The expression of PML/RARa in murine Sca1 þ /linÀ HSC blocks differentiation induced by G/GM-CSF, maintaining them at an early stem cell stage with high c-kit and Sca1 expression levels. 43 Also, erythroid as well as megakaryocytic differentiation is blocked by the expression of PML/RARa in the respective cell models. 44, 45 Therefore, one could speculate that in APL, normal hematopoiesis is mainly suppressed by a blockage of the terminal differentiation by the direct expression of PML/RARa at a stem cell level as well as at an already more advanced level of commitment, whereas many data in various mouse models suggest an important role of leukemia as a space-consuming tumor.
PML/RARa and the apoptosis of HSCs
It is widely accepted that AML blasts are disturbed in their capacity to undergo apoptosis. 46 Apoptosis of stem cells is thought to contribute to the regulation of the physiological selfrenewal of the hematopoietic stem cell compartment. The fact that PML/RARa blocks granulocytic differentiation only at the promyelocytic stage raises the question as to whether PML/RARa is able to interfere with other features of HSCs, thus contributing to the pathogenesis of APL.
Defects in normal apoptosis mechanisms due to the presence of PML/RARa might contribute to the promotion of tumor progression. Indeed, apoptosis defects allow oncogene activation and genetic instability to persist, thereby establishing the transformed phenotype. Many oncogenes -such as c-mycdrive the cell cycle and induce pathways of apoptosis, providing protection against tumorigenesis. Thus, defects in apoptosis mechanisms permit survival of cells that harbor activated oncogenes. 46 PML/RARa deregulates the expression of c-myc (our own unpublished data).
The cell and animal models of APL are complicated by the fact that, in contrast to BCR/ABL, the APL-associated translocation products are not classical oncogenes. BCR/ABL -like other ABL-fusion proteins -abolishes contact inhibition as well as anchorage-dependent growth of nontransformed fibroblasts and allow factor-independent growth of hematopoietic progenitors, an effect further enhanced by the deregulation of normal apoptosis pathways. 47 In contrast to BCR/ABL, PML/RARa is only able to create a state of refractoriness against apoptosis induced by factor-withdrawal, but it is unable to induce factorindependent growth. 48 Furthermore, PML/RARa inhibits apoptosis in U937 cells induced by serum starvation as well as by the exposure to tumor necrosis factor a (TNFa).
10,49
How may PML/RARa interfere with normal apoptosis pathways of the stem cell?
The effects of PML/RARa on apoptosis have been mainly attributed to the fact that in APL -cells, the function of the wild-type PML may be disrupted by a dominant-negative PML/ RARa, although definitive confirmation of this hypothesis is still lacking.
PML is a growth suppressor that regulates cell cycle progression and induces cell death. [50] [51] [52] The observation that PML inhibits transformation of rat and mice 3T3 cells by several oncogenes such as RAS, neu, RAS/c-myc, and mutant p53 established PML as a tumor suppressor. [53] [54] [55] [56] [57] Furthermore, PML is an isoform -specifically involved in the regulation of p53-dependent senescence in embryonic fibroblasts expressing activated RAS. [58] [59] [60] [61] Indirect evidence for an antitumorigenic activity of PML is provided by the fact that PML À/À mice and PML À/À cells are less responsive to apoptosis-inducing stimuli such as Fas, TNF, ceramide, INFs, and ionizing radiation than PML þ / þ mice and PML þ / þ cells. 62 The antileukemic role of PML in APL was proven by the fact that the expression of PML/RARa in PML À/À mice leads to a higher incidence of leukemic mice and an earlier onset as compared to PML/RARa in a PML þ / þ context. 63 One can postulate several mechanisms by which PML/RARa interferes with the putative tumor-suppressive function of PML such as (i) dose reduction of PML by heterozygosity; (ii) formation of PML-PML/RARa hetero-oligomers given the fact that the PML/RARa-induced phenotype is strictly related to its capacity to form HMW complexes in vivo; 15, 42, 64 the disruption of the PML-NBs and the fact that PML and PML/RARa interact in vitro 65 indicate that PML is contained in the PML/RARarelated HMW complexes and may be sequestered into the 'PML/ RARa microspeckles', even if definitive confirmation is still lacking; and (iii) interaction of PML/RARa with physiological PML-interaction partners, thereby sequestering components of the PML-NBs to the 'PML/RARa microspeckles'.
The interference of PML/RARa with the functionality of PML might lead to a deregulation of p53 activity. It has been shown that p53 is modified in the PML-NBs either by phosphorylation by HipK2 [66] [67] [68] or acetylation through the histone-acetyltransferase activity of CBP. 69 The frequency of p53 mutations in AML and APL is low. 70 One could speculate that the disruption of PML-NBs also interferes with the regulation of p53 either by delocalization of p53 from the PML-NBs into the PML/ RARa 'microspeckles' or by recruitment of deacetylase activity by the PML/RARa fusion protein to p53, thereby protecting PML/ RARa-positive blasts from apoptosis induced by DNA-damaging agents. With respect to such a direct interference of PML/RARa on p53 function, one has to consider that the isoform specificity of PML is given by the PML-C-terminus, which is not present in the PML/RARa fusion protein. 71 A reduction of PML functionality could also unmask the transformation activity of the eucaryotic initiation factor 4E (eIF-4E). The eIF-4E is a cap binding protein that regulates the nucleocytoplasmic transport of a subset of transcripts including Cyclin D1. 72 Overexpression of eIF-4E increases the protein level of Cyclin D1 by augmenting its cytoplasmic mRNA, 73 and moreover overexpression of eIF-4E promotes growth and oncogenic transformation. 74 PML and eIF-4E colocalize in the PML-NBs and directly interact through the PML RING domain. 75 PML reduces the affinity of eIF4E for its substrate m 7 G cap of mRNA, causing a reduction of the Cyclin D1 level and a subsequent inhibition of transformation. 75 How do other APL-associated fusion proteins interfere with PML function?
The fact that the influence of PML/RARa on apoptosis is mainly attributed to the disruption of PML function raises the question as to whether the other APL-associated fusion proteins are able to interfere with the functionality of the PML-NBs or if a possible influence on the apoptotic behavior of the respective APL blasts might be due to alternative mechanisms.
In contrast to PML/RARa, the presence of PLZF/RARa as well as the NPM/RARa fusion proteins does not lead to disruption of the PML-NBs. [76] [77] [78] To thus answer the question whether the other APL-associated fusion proteins are able to influence the functionality of the PML-NBs, it is indispensable to disclose properties shared between PML and the other partners of RARa in the APL-associated translocation products.
Whether PLZF is a component of the PML-NBs is controversially discussed, and the mechanisms by which PLZF may interfere with PML-mediated pathways remain to be disclosed. The lack of PML-NB disruption in PLZF/RARa-positive cells does not clarify this issue, because the only protein critical for the integrity of the PML-NBs is PML itself. 79 Similar to PML, PLZF is located in nuclear structures that appear in the immunofluorescence as 'dots'. It has been demonstrated that PML-'dots' and PLZF-'dots' colocalize in CD34 þ cells. 77 In contrast, in KG1 cells and in the PLZF-negative U937 transfected with a PLZFharboring expression vector, PML and PLZF are localized in adjacent but functionally distinct NBs. 76 Further evidence that the PLZF-NBs are functionally distinct from PML-NBs is provided by the fact that PLZF-NBs do not exhibit the known sensitivity of PML-NBs to INFs and to viral sequences. 76 There are several proteins known to localize in the PML-NBs that do not colocalize with PLZF and vice versa (manuscript in preparation). The function of the PLZF-NBs is actually completely unknown.
Nothing is known about the relationship between the other translocation partners of RARa, such as NPM, 78 STAT5b, 80 NUMA, 81 and the PML-NBs. Therefore, it remains to be clarified whether and how the APL-associated translocation products interfere with the functionality of the PML-NBs.
Alterations of the PML-mediated apoptosis pathways may also play a role in other leukemia subentities. In fact, PML-NBs are not only disrupted in cells expressing PML/RARa but are targeted also by other leukemia-defining translocation products such as AML-1/ETO, the product of the AML-M2-associated t(8;21), which induces a highly modified PML and interferes with association of PML to the nuclear matrix. 82, 83 Also, BCR/ABLpositive leukemic lymphoblasts express high amounts of modified PML. 82 BCR/ABL most likely targets PML-NBs by the constitutive activation of RAS. 82 Hence, it seems that the interference with the functionality of the PML-NBs is a common theme in leukemia.
PML/RARa and the potential of HSCs for self-renewal
In the era in which only conventional cytogenetics were available, the t(15;17) was detectable only in about 75% of APL patients. This was attributed to the fact that in contrast to other AML subtypes, APLs exhibit a reduced number of mitoses, indicating an even lower proliferation rate of APL blasts as compared to other AML subtypes. 84 This hypothesis still remains to be confirmed since it would further increase the significance of the differentiation block for the induction of the leukemic phenotype.
Whether PML/RARa is able to interfere with the self-renewal of HSCs independent of the block of differentiation is still to be disclosed. We have shown that PML/RARa as well as PLZF/ RARa activate the Wnt-signaling pathway in vitro and in vivo by the upregulation of g-catenin at the transcriptional level. 43, 85 Activation of the Wnt signaling increases the self-renewal of HSCs. [86] [87] [88] Whether the activation of the Wnt-signaling pathway blocks differentiation of hematopoietic precursors is still unclear. Recent findings show that the exposure of HSCs to Wnt3a leads to increased self-renewal in serum-free conditions, whereas differentiation is possible in a conditioned medium. 88 On the other hand, activation of the Wnt signaling through the overexpression of b-catenin seems to block differentiation. 87 We have recently demonstrated that the overexpression of gcatenin does not block differentiation of a bulk population of Sca1 þ /linÀ cells. Nevertheless, in 'colony formation' (CFC) experiments on HSCs overexpressing g-catenin, we selected a very small cell population of monomorphic, small, and compact CFUs by serial replating. High c-kit and Sca-1 expression proved the very early stem cell stage of these cells. These cells were blocked in their differentiation potential even in the presence of G/GM-CSF. Therefore, one could hypothesize that the activation of the Wnt signaling by the overexpression of g-catenin blocks differentiation only in very early stem cells, but not in already committed hematopoietic progenitors. Thus, there are two levels in which PML/RARa-expressing cells are blocked in their differentiation: one at a very early stem cell level due to the induction of g-catenin, and one at a more advanced level of differentiation due to other factors impaired by PML/RARa or PLZF/RARa, such as C/EBPa. 43 In fact, CFUs morphologically similar to the g-catenin-positive CFUs were frequently detectable also among CFUs expressing PML/RARa or PLZF/RARa. 43 Taken together, these data strongly indicate a double effect of PML/RARa: (i) the block of differentiation of the leukemic promyelocytes resolved by pharmacological dosages of t-RA and (ii) the block of differentiation of the very early leukemic stem cell whose responsiveness to t-RA is still unclear.
Summary
The significance of the blockage of the t-RA-signaling by PML/ RARa and the other APL-associated translocation products for the pathogenesis of APL still has to be definitively proven. The LIC not targeted by therapy is considered to be the source of relapse. In order to further enrich the knowledge about potential therapeutic approaches, future studies need to focus on the LIC and the mechanisms by which the APL-associated translocation products determine its biology. Thus, these studies will define the reasons why, in contrast to arsenic, t-RA alone is unable to induce CRs of long duration. In addition, they could contribute to define the relative importance of various therapeutic approaches for APL.
